TITLE

Saxagliptin + Metformin Extended-release Tablets (Kombiglyze XR)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
January 2011
SOURCE
Internal Medicine Alert;1/15/2011, Vol. 33 Issue 1, p5
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of Saxagliptin + Metformin Extended-release tablets, a dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin combination from Bristol-Myers Squibb by the U.S. Food and Drug Administration (FDA).
ACCESSION #
58516379

 

Related Articles

  • ONGLYZA.  // MPR - Pharmacist's Edition;Sep2009, Vol. 3 Issue 3, pA9 

    The article evaluates the Anglyza, a dipeptidyl peptidase-4 inhibitor, from Bristol-Myers Squibb Co. and AstraZeneca Pharmaceuticals LP.

  • ONGLYZA.  // MPR - Pharmacist's Edition;Winter2009/2010, Vol. 3 Issue 4, pA6 

    The article evaluates the dipeptidyl peptidase-4 (DPP4) inhibitor, Onglyza, from Bristol-Myers Squibb Co. and AstraZeneca PLC.

  • Pharma: Other News To Note.  // BioWorld Today;11/5/2012, Vol. 23 Issue 215, p8 

    This article reports on the decision of the National Institute of Health and Clinical Excellence in Great Britain to recommend Bristol-Myers Squibb Co.'s Yervoy, which is approved in Europe for treating advanced metastatic melanoma, within the final appraisal determination.

  • Pharma: Other News To Note.  // BioWorld Today;11/15/2012, Vol. 23 Issue 223, p7 

    This article reports on an announcement by Bristol-Myers Squibb Co. of New York and AstraZeneca plc of London, England that the European Commission has approved Forxiga (dapaglifozin) tablets for Type II diabetes in the European Union.

  • Kombiglyze XR for diabetes.  // Monthly Prescribing Reference;Dec2010, Vol. 26 Issue 12, pA16 

    The article reports on the approval of Kombiglyze XR, saxagliptin/metformin extended-release tablets for the treatment of type 2 diabetes in adults, from Bristol-Myers Squibb Co. and AstraZeneca PLC.

  • Kombiglyze XR for diabetes.  // MPR - Urologists' Edition;Fall2010/Winter2011, Vol. 7 Issue 1, pA6 

    The article reports on the approval of Kombiglyze XR, which consists saxagliptin and metformin extended-release tablets, from Bristol-Myers Squibb Co. and AstraZeneca for the treatment of type 2 diabetes.

  • Atazanavir Background Documents Available.  // AIDS Treatment News;5/30/2003, Issue 391, p3 

    Reports that Bristol-Myers Squibb's protease inhibitor Atazanavir has been recommended for approval by the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration. Efficacy in reducing cholesterol and triglyceride problems; Effect on other drugs.

  • NEW FORMULATIONS.  // Drug Topics;2/7/2005, Vol. 149 Issue 3, p91 

    Reports on the grant of a U.S. Food and Drug Administration clearance for an oral solution formulation of the atypical antipsychotic drug, Abilify manufactured by the Princeton, New Jersey-based Bristol-Myers Squibb.

  • Bristol-Myers Squibb's. Investor's Business Daily // Investors Business Daily;2/26/2014, pA02 

    The article reports on the approval of the Myalept drug from biopharmaceutical company Bristol-Myers Squibb Co. as the first drug to treat patients with lipodystrophy.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics